KR960041168A - 베타-아드레날린 효능성 작용물질 - Google Patents
베타-아드레날린 효능성 작용물질 Download PDFInfo
- Publication number
- KR960041168A KR960041168A KR1019960015262A KR19960015262A KR960041168A KR 960041168 A KR960041168 A KR 960041168A KR 1019960015262 A KR1019960015262 A KR 1019960015262A KR 19960015262 A KR19960015262 A KR 19960015262A KR 960041168 A KR960041168 A KR 960041168A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- rti
- mammal
- Prior art date
Links
- 239000000808 adrenergic beta-agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 14
- 239000002243 precursor Substances 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- -1 6-aminopyridin-3-yl Chemical group 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- GGJARDHQGODBKP-HNNXBMFYSA-N 2-[4-[2-[[(2r)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]amino]ethoxy]phenoxy]acetic acid Chemical compound C1=NC(N)=CC=C1[C@@H](O)CNCCOC1=CC=C(OCC(O)=O)C=C1 GGJARDHQGODBKP-HNNXBMFYSA-N 0.000 claims 1
- GZJZZQHTBTUBEL-HNNXBMFYSA-N 2-[4-[2-[[(2r)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]amino]ethoxy]phenyl]acetic acid Chemical compound C1=NC(N)=CC=C1[C@@H](O)CNCCOC1=CC=C(CC(O)=O)C=C1 GZJZZQHTBTUBEL-HNNXBMFYSA-N 0.000 claims 1
- KYLBXZZKJCOGCM-AWEZNQCLSA-N 4-[2-[[(2r)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]amino]ethoxy]benzoic acid Chemical compound C1=NC(N)=CC=C1[C@@H](O)CNCCOC1=CC=C(C(O)=O)C=C1 KYLBXZZKJCOGCM-AWEZNQCLSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000020997 lean meat Nutrition 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 208000017497 prostate disease Diseases 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 비만증 및 당뇨병과 같은 질환/증상의 치료를 위한 β-아드레날린 효능성 작용물질에 관한 것이다. 화합물은 하기 일반식(Ⅰ)을 갖는다.
상기 식에서, R1, R2, R3, R4, R5, R6, R7, W, X, Y 및 Z는 명세서에 정의한 바와 같다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (21)
- 하기 일반식을 갖는 화합물, 상기 화합물의 약학적으로 허용가능한 약물 전구체 및 상기 화합물 및 상기 약물 전구체의 약학적으로 허용가능한 염:상기 식에서, R1, R2, R4및 R5는 독립적으로 수소 또는 (C1-C6)알킬이고; R3, R6 및 R7은 독립적으로 수소, 할로겐, (C1-C6)알킬, 니트로, 시아노, 트리플루오로메틸, SO2R8, SO2NR9R10, NR9R10, COR11, CO2R9, (C1-C6)알콕시, NR9SO2R8, NR9COR11, NR9CO2R9또는 OR9이고; R8은 독립적으로 (C1-C6)알킬 또는 (C1-C6)알콕시(C1-C6)알킬이고; R9및 R10은 독립적으로 수소, (C1-C6)알킬, (C3-C8)사이클로알킬 또는 (C1-C6)알콕시(C1-C6)알킬이고; R11은 독립적으로 수소, (C1-C6)알킬, NR9R10, (C3-C8)사이클로알킬 또는 (C1-C6)알콕시(C1-C6)알킬이고; W는 N 또는 CH이거나, 또는 R3가 W에 결합되는 경우에는 CR3(여기서, R3는 H 뿐아니라 R3에 대해 상기 나타낸 어떠한 정의일 수 있다)이고; X 및 Y는 독립적으로 직접 결합이거나, 산소, 황 또는 NR1이고(여기서, R1는 상기 정의된 바와 같다); Z는 (CH2)mOR9, (CH2)nCO2H, (CH2)nCOR11, (CH2)nSO2NR9R10, (CH2)n-NR9SO2R8, (CH2)nP(O)(OR1)(OR2), (CH2)n-O-(CH2)m-, CO2H, (CH2)nO-(CH2)mCOR11, (CH2)nO-(CH2)mP(O)(OR1)-(OR2), (CH2)nO-(CH2)mSO2NR9R10또는 (CH2)n-O-(CH2)m-NR9SO2R8(여기서, R1, R2, R8, R9, R10및 R11은 상기 정의한 바와 같다)이고; m은 1 내지 6이고; n은 0 내지 6이나, 단 Y가 O 또는 S인 경우, n은 0이 아니다.
- 제1항에 있어서, 유리 카복실산인 화합물.
- 제2항에 있어서, X가 산소인 화합물.
- 제3항에 있어서, W가 CH인 화합물.
- 제4항에 있어서, 각 R1, R2, R3, R4, R5, R6및 R7이 H인 화합물.
- 제5항에 있어서, Y가 산소 또는 직접 결합인 화합물.
- 제1항에 있어서, 하기 화합물로 구성되는 그룹으로부터 선택되는 화합물 및 상기 각 화합물의 약학적으로 허용가능한 염: (4-(2-(2-(6-아미노피리딘-3-일)-2(R)-하이드록시에틸아미노)에톡시)페닐)아세트산; (4-(2-(2-(6-아미노피리딘-3-일)-2(R)-하이드록시에틸아미노)에톡시)페닐)아세트산; (4-(2-(2-(6-아미노피리딘-3-일)-2(R)-하이드록시에틸아미노)에톡시)벤조산: 및 4-(2-(2-(6-아미노피리딘-3-일)-2(R)-하이드록시에틸아미노)에톡시)페닐)프로피온산.
- 제7항에 있어서, (4-(2-(2-(6-아미노피리딘-3-일)-2(R)-하이드록시에틸아미노)에톡시)페닐)아세트산인 화합물 및 그의 약학적으로 허용가능한 염.
- 제7항에 있어서, (4-(2-(2-(6-아미노피리딘-3-일)-2(R)-하이드록시에틸아미노)에톡시)페녹시)아세트산인 화합물 및 그의 약학적으로 허용가능한 염.
- 제7항에 있어서, (4-(2-(2-(6-아미노피리딘-3-일)-2(R)-하이드록시에틸아미노)에톡시)벤조산인 화합물 및 그의 약학적으로 허용가능한 염.
- 제7항에 있어서, (4-(2-(2-(6-아미노피리딘-3-일)-2(R)-하이드록시에틸아미노)에톡시)페닐)프로피온산인 화합물 및 그의 약학적으로 허용가능한 염.
- 제1항에서 정의된 효과량의 화합물, 약물 전구체 또는 염, 및 약학적으로 허용가는한 담체를 포함하는 약학 조성물.
- 포유동물의 당뇨병, 과혈당증 및 비만증으로 구성된 그룹중에서 선택된 중상을 치료하는데 유용한 양으로 제1항에서 정의된 일반식(Ⅰ)의 화합물, 그의 약물 전구체 또는 이들 화합물 또는 약물 전구체의 약학적으로 허용가능한 염을 상기 증상의 치료를 필요로 하는 포유류동물에서 투여하는 것을 포함하는 상기 증상의 치료 방법.
- 식용 동물에서 살코기의 함량을 증가시키는데 유효량으로 제1항에서 정의된 일반식(Ⅰ)의 화합물, 그의 약물 전구체 또는 이들 화합물 또는 약물 전구체의 약학적으로 허용가능한 염을 식용 동물에게 투여하는 것을 포함하는, 상기 함량을 증가시키는 방법.
- 포유동물에게 전립선 질환을 치료하는데 유효한 양으로 제1항에서 정의된 바와 같은 일반식(Ⅰ)의 화합물, 그의 약물 전구체 또는 이들 화합물 또는 약물 전구체의 약학적으로 허용가능한 염을 상기 치료를 필요로 하는 포유동물에게 투여하는 것을 포함하는 상기 질환의 치료 방법.
- 포유동물의 장 운동 질환을 치료하는데 유효한 양으로 제1항에서 정의된 일반식(Ⅰ)의 화합물, 그의 약물 전구체 또는 이들 화합물 또는 약물 전구체의 약학적으로 허용가능한 염을 상기 치료를 필요로 하는 포유동물에게 투여하는 것을 포함하는 상기 질환의 치료 방법.
- 포유동물의 우울증을 치료하는데 유효한 양으로 제1항에서 정의된 일반식(Ⅰ)의 화합물, 그의 약물 전구체 또는 이들 화합물 또는 약물 전구체의 약학적으로 허용가능한 염을 상기 치료를 필요로 하는 포유동물에게 투여하는 것을 포함하는 상기 질환의 치료 방법.
- 포유동물의 이상 지혈증을 치료하는데 유효한 양으로 제1항에서 정의된 일반식(Ⅰ)의 화합물, 그의 약물 전구체 또는 이들 화합물 또는 약물 전구체의 약학적으로 허용가능한 염을 상기치료를 필요로 하는 포유동물에게 투여하는 것을 포함하는 상기 질환의 치료 방법.
- 포유동물의 기도 염증성 질환을 치료하는데 유효한 양으로 제1항에서 정의된 일반식(Ⅰ)의 화합물, 그의 약물 전구체 또는 이들 화합물 또는 약물 전구체의 약학적으로 허용가능한 염을 상기 치료를 필요로 하는 포유동물에게 투여하는 것을 포함하는 상기 질환의 치료 방법.
- 제19항에 있어서, 상기 기도 염증성 질환이 천식인 방법.
- 하기 화합물로 구성되는 그룹으로부터 선택되는 화합물:상기 식에서, PG는 통상적인 보호 그룹이고, R은 알킬 그룹이고, R1, R4및 R5는 독립적으로 수소 또는 (C1-C6)알킬이고, R3, R6및 R7은 독립적으로 수소, 할로겐, (C1-C6)알킬, 니트로, 시아노, 트리플루오로메틸, SO2R8, SO2NR9R10, NR9R10, COR11, CO2R9, (C1-C6)알콕시, NR9SO2R8, NR9COR11, NR9CO2R9또는 OR9이고; R8은 독립적으로 (C1-C6)알킬 또는 (C1-C6)알콕시(C1-C6)알킬이고; R9및 R10은 독립적으로 수소, (C1-C6)알킬, (C3-C8)사이클로알킬 또는 (C1-C6)알콕시(C1-C6)알킬이고; R11은 독립적으로 수소, (C1-C6)알킬, NR9R10, (C3-C8)사이클로알킬 또는 (C1-C6)알콕시(C1-C6)알킬이고 (여기서, R9및 R10은 상기 정의한 바와 같다); W는 N는 CH이거나, 또는 R3가 W에 결합되는 경우에는 CR3(여기서, R3는 H뿐아니라 R3에 대해 상기 나타낸 어떠한 정의일 수 있다)이고; X 및 Y는 독립적으로 직접 결합이거나, 산소, 황 또는 NR1이고; Z (CH2)mOR9, (CH2)nCO2H, (CH2)nCOR11, (CH2)nSO2NR9R10, (CH2)nNR9SO2R8, (CH2)nP(O)(OR1)(OR2), (CH2)n-O-(CH2)m-, CO2H, (CH2)nO-(CH2)mCOR11, (CH2)-nO-(CH2)mP(O)(OR1)-(OR2), (CH2)nO-(CH2)mSO2NR9R10또는 (CH2)n-O-(CH2)m-NR9SO2R8(여기서, R1, R2, R8, R9, R10및 R11은 상기 정의된 바와 같다)이고; m은 1 내지 6이고; n은 0 내지 6이나, 단 Y가 O 또는 S인 경우 n은 0이 아니다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002220399A CA2220399A1 (en) | 1995-05-10 | 1995-05-10 | .beta.-adrenergic agonists |
| PCT/IB1995/000344 WO1996035671A1 (en) | 1995-05-10 | 1995-05-10 | β-ADRENERGIC AGONISTS |
| WOPCT/IB95/00344 | 1995-05-10 | ||
| HU9601240A HUP9601240A1 (en) | 1995-05-10 | 1996-05-09 | Pyridin and pyrimidin derivatives, suitable as beta-adrenerg agonists, pharmaceutical compositions containing the same and their intermediates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960041168A true KR960041168A (ko) | 1996-12-19 |
| KR100190259B1 KR100190259B1 (ko) | 1999-06-01 |
Family
ID=89993954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960015262A KR100190259B1 (ko) | 1995-05-10 | 1996-05-09 | 베타-아드레날린 효능성 작용물질 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5977124A (ko) |
| EP (1) | EP0824519A1 (ko) |
| JP (1) | JPH11504649A (ko) |
| KR (1) | KR100190259B1 (ko) |
| AU (1) | AU706235B2 (ko) |
| BR (1) | BR9602209A (ko) |
| CA (1) | CA2220399A1 (ko) |
| CO (1) | CO4440567A1 (ko) |
| CZ (1) | CZ132196A3 (ko) |
| FI (1) | FI974172A (ko) |
| HU (1) | HUP9601240A1 (ko) |
| IL (1) | IL118115A0 (ko) |
| MX (1) | MX9708621A (ko) |
| NO (1) | NO307049B1 (ko) |
| NZ (1) | NZ286548A (ko) |
| PL (1) | PL314120A1 (ko) |
| SG (1) | SG43365A1 (ko) |
| TR (1) | TR199600358A2 (ko) |
| WO (1) | WO1996035671A1 (ko) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981562A (en) * | 1996-01-30 | 1999-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6031105A (en) * | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
| US6008361A (en) * | 1996-04-09 | 1999-12-28 | Pfizer Inc. | Substituted pyridines |
| CN1237160A (zh) * | 1996-11-14 | 1999-12-01 | 辉瑞大药厂 | 取代的吡啶的制备方法 |
| US6001856A (en) * | 1997-06-13 | 1999-12-14 | Pfizer Inc. | β-adrenergic agonists to reduce a wasting condition |
| EP0920864A1 (en) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| US6657063B1 (en) * | 1998-04-30 | 2003-12-02 | Pfizer Inc. | Combinations of β3 agonists and growth hormone secretagogues |
| US6090942A (en) * | 1998-10-15 | 2000-07-18 | Pfizer Inc. | Process and intermediates for a β3 -adrenergic receptor agonist |
| DE60015036T2 (de) * | 1999-07-23 | 2006-03-02 | Pfizer Products Inc., Groton | Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste |
| WO2001021577A2 (en) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| US6451587B1 (en) | 1999-09-29 | 2002-09-17 | Pfizer Inc. | Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone |
| CN1430603A (zh) * | 2000-04-28 | 2003-07-16 | 旭化成株式会社 | 新型双环化合物 |
| BR0114836A (pt) * | 2000-10-20 | 2003-07-01 | Pfizer Prod Inc | Agonistas de receptores beta-3 adrenérgicos e suas aplicações |
| EP1236723A1 (en) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
| DOP2003000587A (es) * | 2002-02-27 | 2003-08-30 | Pfizer Prod Inc | AGONISTAS DEL RECEPTOR ß3-ADRENERGICO |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| AU2003248352A1 (en) * | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | PROCESSES AND INTERMEDIATES USEFUL IN PREPARING Beta3-ADRENERGIC RECEPTOR AGONISTS |
| WO2003072573A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| US20050075323A1 (en) * | 2003-03-05 | 2005-04-07 | Pfizer Inc | Beta3 adrenergic receptor agonists and uses thereof |
| EP1477167A1 (en) * | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
| GB0312832D0 (en) * | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| US7375100B2 (en) | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
| EP1697301A2 (en) * | 2003-12-23 | 2006-09-06 | Astellas Pharma Inc. | Aminoalcohol derivatives |
| WO2006051373A1 (en) * | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| US20090317376A1 (en) | 2005-06-06 | 2009-12-24 | Georgetown University Medical School | Compositions And Methods For Lipo Modeling |
| BRPI0903206E2 (pt) | 2009-09-01 | 2015-07-28 | Da Silva Antonio Carlos Nunes Ett | Unidade processadora e método de processamento de fraldas e absorventes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358455A (en) * | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
| EP0105053B1 (en) * | 1982-10-01 | 1988-01-20 | Merck & Co. Inc. | Aralkylaminoethanol heterocyclic compounds |
| CA1287061C (en) * | 1986-06-27 | 1991-07-30 | Roche Holding Ltd. | Pyridine ethanolamine derivatives |
| GB8703007D0 (en) * | 1987-02-10 | 1987-03-18 | Glaxo Group Ltd | Chemical compounds |
| US5019578A (en) * | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| NZ226991A (en) * | 1987-11-27 | 1992-03-26 | Merck & Co Inc | Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors |
| US5216170A (en) * | 1989-01-26 | 1993-06-01 | Bayer Aktiengesellschaft | (2-aminopropyl) pyridines useful as intermediates |
| GB9209076D0 (en) * | 1992-04-27 | 1992-06-10 | Ici Plc | Chemical compounds |
| US5599966A (en) * | 1992-10-16 | 1997-02-04 | Byk Nederland Bv | Substituted ethanolamine esters |
| US5726192A (en) * | 1992-12-29 | 1998-03-10 | Smithkline Beecham Corporation | Platelet aggregation inhibiting compounds |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| JPH08509491A (ja) * | 1993-04-26 | 1996-10-08 | 藤沢薬品工業株式会社 | 胃腸疾患の治療に有用なエタノールアミン誘導体 |
| CA2164009A1 (en) * | 1993-06-14 | 1994-12-22 | Robert L. Dow | Secondary amines as antidiabetic and antiobesity agents |
| JPH08165276A (ja) * | 1994-12-14 | 1996-06-25 | Dainippon Pharmaceut Co Ltd | ２−アルキルアミノ−１−フェニルエタノール誘導体 |
-
1995
- 1995-05-10 MX MX9708621A patent/MX9708621A/es not_active Application Discontinuation
- 1995-05-10 JP JP8533903A patent/JPH11504649A/ja active Pending
- 1995-05-10 EP EP95915995A patent/EP0824519A1/en not_active Ceased
- 1995-05-10 WO PCT/IB1995/000344 patent/WO1996035671A1/en not_active Application Discontinuation
- 1995-05-10 US US08/945,551 patent/US5977124A/en not_active Expired - Fee Related
- 1995-05-10 CA CA002220399A patent/CA2220399A1/en not_active Abandoned
-
1996
- 1996-05-02 IL IL11811596A patent/IL118115A0/xx unknown
- 1996-05-03 TR TR96/00358A patent/TR199600358A2/xx unknown
- 1996-05-07 CZ CZ961321A patent/CZ132196A3/cs unknown
- 1996-05-07 SG SG1996009751A patent/SG43365A1/en unknown
- 1996-05-08 PL PL96314120A patent/PL314120A1/xx unknown
- 1996-05-08 CO CO96022964A patent/CO4440567A1/es unknown
- 1996-05-09 AU AU52185/96A patent/AU706235B2/en not_active Ceased
- 1996-05-09 HU HU9601240A patent/HUP9601240A1/hu unknown
- 1996-05-09 KR KR1019960015262A patent/KR100190259B1/ko not_active IP Right Cessation
- 1996-05-09 NZ NZ286548A patent/NZ286548A/en unknown
- 1996-05-09 NO NO961887A patent/NO307049B1/no not_active IP Right Cessation
- 1996-05-10 BR BR9602209A patent/BR9602209A/pt active Search and Examination
-
1997
- 1997-11-07 FI FI974172A patent/FI974172A/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG43365A1 (en) | 1997-10-17 |
| AU5218596A (en) | 1996-11-21 |
| CZ132196A3 (en) | 1997-03-12 |
| MX9708621A (es) | 1998-02-28 |
| JPH11504649A (ja) | 1999-04-27 |
| KR100190259B1 (ko) | 1999-06-01 |
| CO4440567A1 (es) | 1997-05-07 |
| HUP9601240A1 (en) | 1997-09-29 |
| HU9601240D0 (en) | 1996-07-29 |
| WO1996035671A1 (en) | 1996-11-14 |
| TR199600358A2 (tr) | 1996-11-21 |
| FI974172A0 (fi) | 1997-11-07 |
| NO961887D0 (no) | 1996-05-09 |
| BR9602209A (pt) | 1998-04-07 |
| NO961887L (no) | 1996-11-11 |
| AU706235B2 (en) | 1999-06-10 |
| IL118115A0 (en) | 1996-09-12 |
| US5977124A (en) | 1999-11-02 |
| FI974172A (fi) | 1997-11-07 |
| CA2220399A1 (en) | 1996-11-14 |
| NO307049B1 (no) | 2000-01-31 |
| NZ286548A (en) | 1998-03-25 |
| PL314120A1 (en) | 1996-11-12 |
| EP0824519A1 (en) | 1998-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960041168A (ko) | 베타-아드레날린 효능성 작용물질 | |
| US20010012851A1 (en) | Nitric oxide releasing oxindole prodrugs for anagesic, anti-inflammatory and disease-modifying use | |
| CA2373653C (en) | New use of compounds as antibacterial agents | |
| ES2216513T3 (es) | Nuevos analogos heterociclicos de compuestos de difeniletileno. | |
| RU2312106C2 (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
| AU2007235145B2 (en) | Combination treatment of metabolic disorders | |
| KR870007113A (ko) | 5-리포옥시제나제의 저해제로서 신규한 페놀티오에테르 | |
| US20100076037A1 (en) | Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma | |
| KR910002795A (ko) | 2- (아미노아릴) 인돌 및 인돌린, 이의 제조방법 및 약제로서의 용도 | |
| KR950702982A (ko) | 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives) | |
| WO2005012221A1 (ja) | ジフェニルエーテル化合物、その製造方法および用途 | |
| CZ20032927A3 (cs) | Léčení cukrovky typu 2 inhibitory z dipeptidylpeptidázy IV | |
| RU98102959A (ru) | Замещенные бензиламинопиперидины | |
| KR930702287A (ko) | 신규화합물 | |
| JP2015180702A (ja) | 結腸癌発生を予防または低減する方法 | |
| RU2004133670A (ru) | Способ лечения диабета | |
| RU2009131697A (ru) | Применение ингибитора trpm5 для регулирования секреции инсулина и гпп-1 | |
| US20030212074A1 (en) | Phosphate transport inhibitors | |
| WO2008008650A1 (en) | Methods for treating cystic kidney diseases | |
| JP2003526663A (ja) | Ｃｏｍｔ阻害剤の鎮痛剤としての用途 | |
| EP0984012A2 (en) | Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties | |
| RU2005131617A (ru) | Производные простых иминоэфиров и лекарства, содержащие их в качестве активного ингредиента | |
| JP2006507359A (ja) | 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用 | |
| RU2001104880A (ru) | Пиперазиновые производные, обладающие антидиабетической активностью, способы их получения и содержащие их композиции | |
| JP6152387B2 (ja) | Ｉ型およびｉｉ型糖尿病の処置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |